GB202109922D0 - Radiotracers and therapeutics binding to fibroblast activation protein (fap) - Google Patents

Radiotracers and therapeutics binding to fibroblast activation protein (fap)

Info

Publication number
GB202109922D0
GB202109922D0 GBGB2109922.1A GB202109922A GB202109922D0 GB 202109922 D0 GB202109922 D0 GB 202109922D0 GB 202109922 A GB202109922 A GB 202109922A GB 202109922 D0 GB202109922 D0 GB 202109922D0
Authority
GB
United Kingdom
Prior art keywords
radiotracers
fap
activation protein
fibroblast activation
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2109922.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blue Earth Diagnostics Ltd
Original Assignee
Blue Earth Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blue Earth Diagnostics Ltd filed Critical Blue Earth Diagnostics Ltd
Priority to GBGB2109922.1A priority Critical patent/GB202109922D0/en
Publication of GB202109922D0 publication Critical patent/GB202109922D0/en
Priority to PCT/US2022/073544 priority patent/WO2023283627A1/en
Priority to JP2024500469A priority patent/JP2024529307A/ja
Priority to US18/577,580 priority patent/US20240399001A1/en
Priority to EP22777124.3A priority patent/EP4366786A1/en
Priority to KR1020247002851A priority patent/KR20240035488A/ko
Priority to CN202280053524.XA priority patent/CN117836013A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GBGB2109922.1A 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap) Ceased GB202109922D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2109922.1A GB202109922D0 (en) 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
PCT/US2022/073544 WO2023283627A1 (en) 2021-07-09 2022-07-08 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
JP2024500469A JP2024529307A (ja) 2021-07-09 2022-07-08 線維芽細胞活性化タンパク質（ｆａｐ）に結合する放射性トレーサーおよび治療薬
US18/577,580 US20240399001A1 (en) 2021-07-09 2022-07-08 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
EP22777124.3A EP4366786A1 (en) 2021-07-09 2022-07-08 Radiotracers and therapeutics binding to fibroblast activation protein (fap)
KR1020247002851A KR20240035488A (ko) 2021-07-09 2022-07-08 섬유아세포 활성화 단백질(fap)과 결합하는 방사성 트레이서들 및 치료제들
CN202280053524.XA CN117836013A (zh) 2021-07-09 2022-07-08 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2109922.1A GB202109922D0 (en) 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap)

Publications (1)

Publication Number Publication Date
GB202109922D0 true GB202109922D0 (en) 2021-08-25

Family

ID=77353994

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2109922.1A Ceased GB202109922D0 (en) 2021-07-09 2021-07-09 Radiotracers and therapeutics binding to fibroblast activation protein (fap)

Country Status (7)

Country Link
US (1) US20240399001A1 (https=)
EP (1) EP4366786A1 (https=)
JP (1) JP2024529307A (https=)
KR (1) KR20240035488A (https=)
CN (1) CN117836013A (https=)
GB (1) GB202109922D0 (https=)
WO (1) WO2023283627A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024152775A1 (zh) * 2023-01-17 2024-07-25 云合智药（苏州）生物科技有限公司 缀合物、配体单元及其用途
WO2024227137A1 (en) * 2023-04-28 2024-10-31 The Board Of Regents Of The University Of Texas System Structurally-reinforced stable theranostic copper radiopharmaceuticals targeting fibroblast activation protein for cancer diagnosis and therapy
WO2025106926A1 (en) * 2023-11-16 2025-05-22 Praxis Biotech LLC Conjugates targeting fibroblast activation protein and uses thereof
WO2026041109A1 (zh) * 2024-08-23 2026-02-26 苏州博锐创合医药有限公司 成纤维细胞活化蛋白抑制剂及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
WO2019020831A1 (en) 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES
WO2019083990A2 (en) 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
WO2019154886A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
WO2020157184A1 (en) 2019-01-30 2020-08-06 Technische Universität München Cancer diagnostic imaging agents
WO2021005131A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
WO2021005125A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191691A1 (ru) 2019-01-30 2021-11-01 Технише Универзитет Мюнхен Радиоактивная метка, связывающая psma двумя способами, и терапевтическое средство

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
WO2019020831A1 (en) 2017-07-28 2019-01-31 Technische Universität München AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES
WO2019083990A2 (en) 2017-10-23 2019-05-02 The Johns Hopkins University IMAGING AND RADIATION THERAPY AGENTS TARGETING α-FIBROBLAST ACTIVATION PROTEIN α (FAP-α)
WO2019154886A1 (en) 2018-02-06 2019-08-15 Universität Heidelberg Fap inhibitor
WO2020157184A1 (en) 2019-01-30 2020-08-06 Technische Universität München Cancer diagnostic imaging agents
WO2021005131A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
WO2021005125A1 (en) 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LINDNER ET AL., BIOCONJUGATE CHEMISTRY, vol. 25, 2014, pages 738 - 749
RUI L. ET AL., CANCER BIOLOGY & THERAPY, vol. 13, no. 3, 2012, pages 123 - 129
ZHANG ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, 2010, pages 12711 - 12716

Also Published As

Publication number Publication date
US20240399001A1 (en) 2024-12-05
CN117836013A (zh) 2024-04-05
WO2023283627A1 (en) 2023-01-12
JP2024529307A (ja) 2024-08-06
KR20240035488A (ko) 2024-03-15
EP4366786A1 (en) 2024-05-15
WO2023283627A9 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
GB202109922D0 (en) Radiotracers and therapeutics binding to fibroblast activation protein (fap)
IL288610A (en) Recombinant fap binding proteins and their use
ZA202212246B (en) Compounds specific to coronavirus s protein and uses thereof
GB2613715B (en) Binding proteins specific for RAS neoantigens and uses thereof
IL276497A (en) Fibrolast binders and their use
SG11202010237RA (en) Fusion protein binding to cd47 protein and application thereof
MX2010002968A (es) Proteinas de enlace de antigeno gm-csf humano.
EP3946451A4 (en) FIBROBLAST ACTIVATING PROTEIN BINDING AGENTS AND USE THEREOF
DK3917626T3 (da) Psma-bindende dualmodusradiotracer og terapeutika
MX2009011870A (es) Polipeptidos de interferon beta modificados y usos de los mismos.
IL312043A (en) Mesothelin binding proteins and their uses
EP3882266A4 (en) LRIG-1 PROTEIN SPECIFIC BINDING MOLECULE AND USE THEREOF
IL318084A (en) Antibodies that bind to HUMAN PAD4 and its uses
IL304584A (en) hhla2 binding agents with novel activity
IL316176A (en) SIGLEC-8 binding proteins and their uses
GB201914327D0 (en) Improvements in and relating to dynamic path switching
MX2008000230A (es) Proteinas de enlace il-6.
IL285282A (en) Antibodies that bind to Plasmodium circumsporozoite protein and their uses
IL316958A (en) PTK7-binding proteins with pH-dependent binding and their uses
DK1790720T3 (da) Polypeptid med aktivitet af umættende omega3-fedtsyre, polynukleotid der koder for polypeptidet og anvendelse deraf
EP4291250C0 (en) DUAL-MODE RADIOTRACOR AND THERAPEUTIC AGENTS
GB201918030D0 (en) Improvements in, or relating to, binders and/or coatings
IL311185A (en) MOG-binding proteins and uses thereof
IL316414A (en) Compositions containing modified aneloid virus capsid proteins and their uses
IL308973A (en) ANTI-CTLA-4 binding proteins and methods of using them

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)